MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer

go back to reference F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018)CrossRef F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018)CrossRef

go back to reference A. Oba, C. Croce, P. Hosokawa, C. Meguid, R.J. Torphy, M.H. Al-Musawi, S. Ahrendt, A. Gleisner, R.D. Schulick, and M. Del Chiaro, Prognosis based definition of resectability in pancreatic cancer: a road map to new guidelines. Ann. Surg. (2020). https://doi.org/10.1097/SLA.0000000000003859 Online ahead of print.CrossRefPubMed A. Oba, C. Croce, P. Hosokawa, C. Meguid, R.J. Torphy, M.H. Al-Musawi, S. Ahrendt, A. Gleisner, R.D. Schulick, and M. Del Chiaro, Prognosis based definition of resectability in pancreatic cancer: a road map to new guidelines. Ann. Surg. (2020). https://​doi.​org/​10.​1097/​SLA.​0000000000003859​ Online ahead of print.CrossRefPubMed

go back to reference C.M. Kang, S.H. Lee, H.K. Hwang, M. Yun, W.J. Lee, Preoperative volume-based PET parameter, MTV2.5, as a potential surrogate marker for tumor biology and recurrence in resected pancreatic cancer. Medicine 95, 1–8 (2016)CrossRef C.M. Kang, S.H. Lee, H.K. Hwang, M. Yun, W.J. Lee, Preoperative volume-based PET parameter, MTV2.5, as a potential surrogate marker for tumor biology and recurrence in resected pancreatic cancer. Medicine 95, 1–8 (2016)CrossRef

go back to reference S.H. Lee, H.K. Hwang, W.J. Lee, M. Yun, C.M. Kang, Preoperative metabolic tumor volume2.5 associated with early systemic metastasis in resected pancreatic cancer: a transcriptome-wide analysis. Gut Liver 13, 356–365 (2019)CrossRef S.H. Lee, H.K. Hwang, W.J. Lee, M. Yun, C.M. Kang, Preoperative metabolic tumor volume2.5 associated with early systemic metastasis in resected pancreatic cancer: a transcriptome-wide analysis. Gut Liver 13, 356–365 (2019)CrossRef

go back to reference Z. Ding, S. Zu, J. Gu, Evaluating the molecule-based prediction of clinical drug responses in cancer. Bioinformatics 32, 2891–2895 (2016)CrossRef Z. Ding, S. Zu, J. Gu, Evaluating the molecule-based prediction of clinical drug responses in cancer. Bioinformatics 32, 2891–2895 (2016)CrossRef

go back to reference G.H. Baek, Y.F. Tse, Z. Hu, D. Cox, N. Buboltz, P. McCue, C.J. Yeo, M.A. White, R.J. DeBerardinis, E.S. Knudsen, A.K. Witkiewicz, MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 9, 2233–2249 (2014)CrossRef G.H. Baek, Y.F. Tse, Z. Hu, D. Cox, N. Buboltz, P. McCue, C.J. Yeo, M.A. White, R.J. DeBerardinis, E.S. Knudsen, A.K. Witkiewicz, MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 9, 2233–2249 (2014)CrossRef

go back to reference A. Javaeed, S.K. Ghauri, MCT4 has a potential to be used as a prognostic biomarker - a systematic review and meta-analysis. Oncol. Rev. 13, 88–96 (2019)CrossRef A. Javaeed, S.K. Ghauri, MCT4 has a potential to be used as a prognostic biomarker - a systematic review and meta-analysis. Oncol. Rev. 13, 88–96 (2019)CrossRef

go back to reference T. Seufferlein, J. Mayerle, Pancreatic cancer in 2015: Precision medicine in pancreatic cancer-fact or fiction? Nat. Rev. Gastroenterol. Hepatol. 13, 74–75 (2016)CrossRef T. Seufferlein, J. Mayerle, Pancreatic cancer in 2015: Precision medicine in pancreatic cancer-fact or fiction? Nat. Rev. Gastroenterol. Hepatol. 13, 74–75 (2016)CrossRef

go back to reference P. Jiang, S. Gu, D. Pan, J. Fu, A. Sahu, X. Hu, Z. Li, N. Traugh, X. Bu, B. Li, J. Liu, G.J. Freeman, M.A. Brown, K.W. Wucherpfennig, X.S. Liu, Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018)CrossRef P. Jiang, S. Gu, D. Pan, J. Fu, A. Sahu, X. Hu, Z. Li, N. Traugh, X. Bu, B. Li, J. Liu, G.J. Freeman, M.A. Brown, K.W. Wucherpfennig, X.S. Liu, Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550–1558 (2018)CrossRef

go back to reference J.P. Neoptolemos, J. Kleeff, P. Michl, E. Costello, W. Greenhalf, D.H. Palmer, Therapeutic developments in pancreatic cancer: current and future perspectives. Nat. Rev. Gastroenterol. Hepatol. 15, 333–348 (2018)CrossRef J.P. Neoptolemos, J. Kleeff, P. Michl, E. Costello, W. Greenhalf, D.H. Palmer, Therapeutic developments in pancreatic cancer: current and future perspectives. Nat. Rev. Gastroenterol. Hepatol. 15, 333–348 (2018)CrossRef

go back to reference S. Lawrence, V. Adsay, G. Petersen, D. Klimstra, N. Bardeesy, M.D.M. Leiserson, R. Bowlby, K. Kasaian, I. Birol, K.L. Mungall, S. Sadeghi, J.N. Weinstein, P.T. Spellman,Y. Liu, L.T. Amundadottir, J. Tepper, A.D. Singhi, R. Dhir, D. Paul, T. Smyrk, L. Zhang,P. Kim, J. Bowen, J. Frick, J.M. Gastier-Foster, M. Gerken, K. Lau, K.M. Leraas, T.M. Lichtenberg, N.C. Ramirez, J. Renkel, M. Sherman, L. Wise, P. Yena, E. Zmuda, J. Shih, A. Ally, M. Balasundaram, R. Carlsen, A. Chu, E. Chuah, A. Clarke, N. Dhalla, R.A.Holt, S.J.M. Jones, D. Lee, Y. Ma, M.A. Marra, M. Mayo, R.A. Moore, A.J. Mungall, J.E. Schein, P. Sipahimalani, A. Tam, N. Thiessen, K. Tse, T. Wong, D. Brooks, J.T. Auman, S. Balu, T. Bodenheimer, D.N. Hayes, A.P. Hoyle, S.R. Jefferys, C.D. Jones, S. Meng, P.A. Mieczkowski, L.E. Mose, C.M. Perou, A.H. Perou, J. Roach, Y. Shi, J.V. Simons, T. Skelly, M.G. Soloway, D. Tan, U. Veluvolu, J.S. Parker, M.D. Wilkerson, A. Korkut, Y. Senbabaoglu,P. Burch, R. McWilliams, K. Chaffee, A. Oberg, W. Zhang, M.C. Gingras, D.A. Wheeler, L. Xi, M. Albert, J. Bartlett, H. Sekhon, Y. Stephen, Z. Howard, M. Judy, A. Breggia, R.T. Shroff, S. Chudamani, J. Liu, L. Lolla, R. Naresh, T. Pihl, Q. Sun, Y. Wan, Y. Wu, S. Jennifer, K. Roggin, K.F. Becker, M. Behera, J. Bennett, L. Boice, E. Burks, C.G. Carlotti Junior, J. Chabot, D. Pretti da Cunha Tirapelli, J. Sebastião dos Santos, M. Dubina, J. Eschbacher, M. Huang, L. Huelsenbeck-Dill, R. Jenkins, A. Karpov, R. Kemp, V. Lyadov, S. Maithel, G. Manikhas, E. Montgomery, H. Noushmehr, A. Osunkoya,T. Owonikoko, O. Paklina, O. Potapova, S. Ramalingam, W.K. Rathmell, K. Rieger-Christ, C. Saller, G. Setdikova, A. Shabunin, G. Sica, T. Su, T. Sullivan, P. Swanson, K. Tarvin, M. Tavobilov, L.B. Thorne, S. Urbanski, O. Voronina, T. Wang, D. Crain, E. Curley, J. Gardner, D. Mallery, S. Morris, J. Paulauskis, R. Penny, C. Shelton, T. Shelton, K.P. Janssen, O. Bathe, N. Bahary, J. Slotta-Huspenina, A. Johns, H. Hibshoosh, R.F. Hwang, A. Sepulveda, A. Radenbaugh, S.B. Baylin, M. Berrios, M.S. Bootwalla, A. Holbrook, P.H. Lai, D.T. Maglinte, S. Mahurkar, T.J. Triche, D.J. Van Den Berg, D.J. Weisenberger, L. Chin, R. Kucherlapati, M. Kucherlapati, A. Pantazi, P. Park, G. Saksena, D. Voet, P. Lin, S. Frazer, T. Defreitas, S. Meier, L. Chin, S.Y. Kwon, Y.H. Kim, S.J. Park, S.S. Han, S.H. Kim, H. Kim, E. Furth, M. Tempero, C. Sander, A. Biankin, D. Chang, P. Bailey, A. Gill, J. Kench, S. Grimmond, A. Johns, A.P. Cancer Genome Initiative (APGI, R. Postier, R. Zuna, H. Sicotte, J.A. Demchok, M.L. Ferguson, C.M. Hutter, K.R. Mills Shaw, M. Sheth, H.J. Sofia, R. Tarnuzzer, Z. Wang, L. Yang, J. (julia) Zhang, I. Felau, and J.C. Zenklusen, Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185-203 (2017) S. Lawrence, V. Adsay, G. Petersen, D. Klimstra, N. Bardeesy, M.D.M. Leiserson, R. Bowlby, K. Kasaian, I. Birol, K.L. Mungall, S. Sadeghi, J.N. Weinstein, P.T. Spellman,Y. Liu, L.T. Amundadottir, J. Tepper, A.D. Singhi, R. Dhir, D. Paul, T. Smyrk, L. Zhang,P. Kim, J. Bowen, J. Frick, J.M. Gastier-Foster, M. Gerken, K. Lau, K.M. Leraas, T.M. Lichtenberg, N.C. Ramirez, J. Renkel, M. Sherman, L. Wise, P. Yena, E. Zmuda, J. Shih, A. Ally, M. Balasundaram, R. Carlsen, A. Chu, E. Chuah, A. Clarke, N. Dhalla, R.A.Holt, S.J.M. Jones, D. Lee, Y. Ma, M.A. Marra, M. Mayo, R.A. Moore, A.J. Mungall, J.E. Schein, P. Sipahimalani, A. Tam, N. Thiessen, K. Tse, T. Wong, D. Brooks, J.T. Auman, S. Balu, T. Bodenheimer, D.N. Hayes, A.P. Hoyle, S.R. Jefferys, C.D. Jones, S. Meng, P.A. Mieczkowski, L.E. Mose, C.M. Perou, A.H. Perou, J. Roach, Y. Shi, J.V. Simons, T. Skelly, M.G. Soloway, D. Tan, U. Veluvolu, J.S. Parker, M.D. Wilkerson, A. Korkut, Y. Senbabaoglu,P. Burch, R. McWilliams, K. Chaffee, A. Oberg, W. Zhang, M.C. Gingras, D.A. Wheeler, L. Xi, M. Albert, J. Bartlett, H. Sekhon, Y. Stephen, Z. Howard, M. Judy, A. Breggia, R.T. Shroff, S. Chudamani, J. Liu, L. Lolla, R. Naresh, T. Pihl, Q. Sun, Y. Wan, Y. Wu, S. Jennifer, K. Roggin, K.F. Becker, M. Behera, J. Bennett, L. Boice, E. Burks, C.G. Carlotti Junior, J. Chabot, D. Pretti da Cunha Tirapelli, J. Sebastião dos Santos, M. Dubina, J. Eschbacher, M. Huang, L. Huelsenbeck-Dill, R. Jenkins, A. Karpov, R. Kemp, V. Lyadov, S. Maithel, G. Manikhas, E. Montgomery, H. Noushmehr, A. Osunkoya,T. Owonikoko, O. Paklina, O. Potapova, S. Ramalingam, W.K. Rathmell, K. Rieger-Christ, C. Saller, G. Setdikova, A. Shabunin, G. Sica, T. Su, T. Sullivan, P. Swanson, K. Tarvin, M. Tavobilov, L.B. Thorne, S. Urbanski, O. Voronina, T. Wang, D. Crain, E. Curley, J. Gardner, D. Mallery, S. Morris, J. Paulauskis, R. Penny, C. Shelton, T. Shelton, K.P. Janssen, O. Bathe, N. Bahary, J. Slotta-Huspenina, A. Johns, H. Hibshoosh, R.F. Hwang, A. Sepulveda, A. Radenbaugh, S.B. Baylin, M. Berrios, M.S. Bootwalla, A. Holbrook, P.H. Lai, D.T. Maglinte, S. Mahurkar, T.J. Triche, D.J. Van Den Berg, D.J. Weisenberger, L. Chin, R. Kucherlapati, M. Kucherlapati, A. Pantazi, P. Park, G. Saksena, D. Voet, P. Lin, S. Frazer, T. Defreitas, S. Meier, L. Chin, S.Y. Kwon, Y.H. Kim, S.J. Park, S.S. Han, S.H. Kim, H. Kim, E. Furth, M. Tempero, C. Sander, A. Biankin, D. Chang, P. Bailey, A. Gill, J. Kench, S. Grimmond, A. Johns, A.P. Cancer Genome Initiative (APGI, R. Postier, R. Zuna, H. Sicotte, J.A. Demchok, M.L. Ferguson, C.M. Hutter, K.R. Mills Shaw, M. Sheth, H.J. Sofia, R. Tarnuzzer, Z. Wang, L. Yang, J. (julia) Zhang, I. Felau, and J.C. Zenklusen, Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185-203 (2017)

go back to reference S.B. Dreyer, M. Pinese, N.B. Jamieson, C.J. Scarlett, E.K. Colvin, M. Pajic, A.L. Johns, J.L. Humphris, J. Wu, M.J. Cowley, A. Chou, A.M. Nagrial, L. Chantrill, V.T. Chin, M.D. Jones, K. Moran-Jones, C.R. Carter, E.J. Dickson, J.S. Samra, N.D. Merrett, A.J. Gill, J.G. Kench, F. Duthie, D.K. Miller, S. Cooke, D. Aust, T. Knösel, P. Rümmele, R. Grützmann, C. Pilarsky, N.Q. Nguyen, E.A. Musgrove, P.J. Bailey, C.J. McKay, A.V. Biankin, D.K. Chang, Australian Pancreatic Cancer Genome Initiative, and Glasgow Precision Oncology Laboratory, precision oncology in surgery: patient selection for operable pancreatic cancer. Ann. Surg. 272, 366–376 (2020)CrossRef S.B. Dreyer, M. Pinese, N.B. Jamieson, C.J. Scarlett, E.K. Colvin, M. Pajic, A.L. Johns, J.L. Humphris, J. Wu, M.J. Cowley, A. Chou, A.M. Nagrial, L. Chantrill, V.T. Chin, M.D. Jones, K. Moran-Jones, C.R. Carter, E.J. Dickson, J.S. Samra, N.D. Merrett, A.J. Gill, J.G. Kench, F. Duthie, D.K. Miller, S. Cooke, D. Aust, T. Knösel, P. Rümmele, R. Grützmann, C. Pilarsky, N.Q. Nguyen, E.A. Musgrove, P.J. Bailey, C.J. McKay, A.V. Biankin, D.K. Chang, Australian Pancreatic Cancer Genome Initiative, and Glasgow Precision Oncology Laboratory, precision oncology in surgery: patient selection for operable pancreatic cancer. Ann. Surg. 272, 366–376 (2020)CrossRef

go back to reference S.B. Dreyer, M. Pinese, N.B. Jamieson, C.J. Scarlett, E.K. Colvin, M. Pajic, A.L. Johns, J.L. Humphris, J. Wu, M.J. Cowley, A. Chou, A.M. Nagrial, L. Chantrill, V.T. Chin, M.D. Jones, K. Moran-Jones, C.R. Carter, E.J. Dickson, J.S. Samra, N.D. Merrett, A.J. Gill, J.G. Kench, F. Duthie, D.K. Miller, S. Cooke, D. Aust, T. Knösel, P. Rümmele, R. Grützmann, C. Pilarsky, N.Q. Nguyen, E.A. Musgrove, P.J. Bailey, C.J. McKay, A.V. Biankin, D.K. Chang, Australian Pancreatic Cancer Genome Initiative, and Glasgow Precision Oncology Laboratory, precision oncology in surgery: patient selection for operable pancreatic cancer. Ann. Surg. 1, 366–376 (2018) S.B. Dreyer, M. Pinese, N.B. Jamieson, C.J. Scarlett, E.K. Colvin, M. Pajic, A.L. Johns, J.L. Humphris, J. Wu, M.J. Cowley, A. Chou, A.M. Nagrial, L. Chantrill, V.T. Chin, M.D. Jones, K. Moran-Jones, C.R. Carter, E.J. Dickson, J.S. Samra, N.D. Merrett, A.J. Gill, J.G. Kench, F. Duthie, D.K. Miller, S. Cooke, D. Aust, T. Knösel, P. Rümmele, R. Grützmann, C. Pilarsky, N.Q. Nguyen, E.A. Musgrove, P.J. Bailey, C.J. McKay, A.V. Biankin, D.K. Chang, Australian Pancreatic Cancer Genome Initiative, and Glasgow Precision Oncology Laboratory, precision oncology in surgery: patient selection for operable pancreatic cancer. Ann. Surg. 1, 366–376 (2018)

go back to reference M.A. Tempero, D. Klimstra, J. Berlin, T. Hollingsworth, P. Kim, N. Merchant, M. Moore, D. Pleskow, A. Wang-Gillam, A.M. Lowy, Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin. Cancer Res. 19, 538–540 (2013)CrossRef M.A. Tempero, D. Klimstra, J. Berlin, T. Hollingsworth, P. Kim, N. Merchant, M. Moore, D. Pleskow, A. Wang-Gillam, A.M. Lowy, Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin. Cancer Res. 19, 538–540 (2013)CrossRef

go back to reference H.K. Hwang, S.H. Lee, H.I. Kim, S.H. Kim, J. Choi, C.M. Kang, W.J. Lee, Yonsei criteria, a potential linkage to intratumoral Foxp3 + / CD8 + ratio for the prediction of oncologic outcomes in resected left-sided pancreatic cancer. Yonsei Med. J. 61, 291–300 (2020)CrossRef H.K. Hwang, S.H. Lee, H.I. Kim, S.H. Kim, J. Choi, C.M. Kang, W.J. Lee, Yonsei criteria, a potential linkage to intratumoral Foxp3 + / CD8 + ratio for the prediction of oncologic outcomes in resected left-sided pancreatic cancer. Yonsei Med. J. 61, 291–300 (2020)CrossRef

go back to reference S.Y. Rho, M. Yun, C.M. Kang, S.H. Lee, H.K. Hwang, W.J. Lee, Different biological behaviors in left-sided pancreatic cancer according to Yonsei criteria: proposal of a modified Yonsei criteria score. Pancreatology 18, 990–995 (2018)CrossRef S.Y. Rho, M. Yun, C.M. Kang, S.H. Lee, H.K. Hwang, W.J. Lee, Different biological behaviors in left-sided pancreatic cancer according to Yonsei criteria: proposal of a modified Yonsei criteria score. Pancreatology 18, 990–995 (2018)CrossRef

go back to reference J.U. Chong, S.H. Kim, H.K. Hwang, C.M. Kang, W.J. Lee, Yonsei criteria: a clinical reflection of stage I left-sided pancreatic cancer. Oncotarget 8, 110830–110836 (2017)CrossRef J.U. Chong, S.H. Kim, H.K. Hwang, C.M. Kang, W.J. Lee, Yonsei criteria: a clinical reflection of stage I left-sided pancreatic cancer. Oncotarget 8, 110830–110836 (2017)CrossRef

go back to reference S.H. Lee, H.K. Hwang, C.M. Kang, W.J. Lee, The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-matched analysis. Surg. Endosc. 31, 4656 (2017) S.H. Lee, H.K. Hwang, C.M. Kang, W.J. Lee, The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-matched analysis. Surg. Endosc. 31, 4656 (2017)

go back to reference J.U. Chong, H.K. Hwang, J.H. Lee, M. Yun, C.M. Kang, W.J. Lee, Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer. PLoS One 12, 1–15 (2017)CrossRef J.U. Chong, H.K. Hwang, J.H. Lee, M. Yun, C.M. Kang, W.J. Lee, Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer. PLoS One 12, 1–15 (2017)CrossRef

go back to reference V.L. Payen, E. Mina, V.F. Van Hée, P.E. Porporato, P. Sonveaux, Monocarboxylate transporters in cancer. Mol. Metab. 33, 48–66 (2020)CrossRef V.L. Payen, E. Mina, V.F. Van Hée, P.E. Porporato, P. Sonveaux, Monocarboxylate transporters in cancer. Mol. Metab. 33, 48–66 (2020)CrossRef

go back to reference K.J. Labori, M.H. Katz, C.W. Tzeng, B.A. Bjørnbeth, M. Cvancarova, B. Edwin, E.H. Kure, T.J. Eide, S. Dueland, T. Buanes, I.P. Glsadhaug, Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - a population-based cohort study. Acta Oncol. 55, 265–277 (2016)CrossRef K.J. Labori, M.H. Katz, C.W. Tzeng, B.A. Bjørnbeth, M. Cvancarova, B. Edwin, E.H. Kure, T.J. Eide, S. Dueland, T. Buanes, I.P. Glsadhaug, Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - a population-based cohort study. Acta Oncol. 55, 265–277 (2016)CrossRef

go back to reference S. Yu, C. Zhang, K.P.K. Xie, Therapeutic resistance of pancreatic cancer: roadmap to its reversal. Biochim. Biophys. Acta (BBA) - Rev. Cancer 1875, 188461 (2020)CrossRef S. Yu, C. Zhang, K.P.K. Xie, Therapeutic resistance of pancreatic cancer: roadmap to its reversal. Biochim. Biophys. Acta (BBA) - Rev. Cancer 1875, 188461 (2020)CrossRef

go back to reference M. Sinn, M. Bahra, T. Liersch, K. Gellert, H. Messmann, W. Bechstein, D. Waldschmidt, L. Jacobasch, M. Wilhelm, B.M. Rau, R. Grützmann, A. Weinmann, G. Maschmeyer, U. Pelzer, J.M. Stieler, J.K. Striefler, M. Ghadimi, S. Bischoff, B. Dörken, H. Oettle, H. Riess, CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after r0 resection of pancreatic cancer: a multicenter randomized phase III trial. J. Clin. Oncol. 35, 3330–3337 (2017)CrossRef M. Sinn, M. Bahra, T. Liersch, K. Gellert, H. Messmann, W. Bechstein, D. Waldschmidt, L. Jacobasch, M. Wilhelm, B.M. Rau, R. Grützmann, A. Weinmann, G. Maschmeyer, U. Pelzer, J.M. Stieler, J.K. Striefler, M. Ghadimi, S. Bischoff, B. Dörken, H. Oettle, H. Riess, CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after r0 resection of pancreatic cancer: a multicenter randomized phase III trial. J. Clin. Oncol. 35, 3330–3337 (2017)CrossRef

go back to reference K. Uesaka, N. Boku, A. Fukutomi, Y. Okamura, M. Konishi, I. Matsumoto, Y. Kaneoka, Y. Shimizu, S. Nakamori, H. Sakamoto, S. Morinaga, O. Kainuma, K. Imai, N. Sata, S. Hishinuma, H. Ojima, R. Yamaguchi, S. Hirano, T. Sudo, Y. Ohashi, Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388, 248–257 (2016)CrossRef K. Uesaka, N. Boku, A. Fukutomi, Y. Okamura, M. Konishi, I. Matsumoto, Y. Kaneoka, Y. Shimizu, S. Nakamori, H. Sakamoto, S. Morinaga, O. Kainuma, K. Imai, N. Sata, S. Hishinuma, H. Ojima, R. Yamaguchi, S. Hirano, T. Sudo, Y. Ohashi, Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388, 248–257 (2016)CrossRef

go back to reference Y. Hagiwara, Y. Ohashi, K. Uesaka, N. Boku, A. Fukutomi, Y. Okamura, M. Konishi, I. Matsumoto, Y. Kaneoka, Y. Shimizu, S. Nakamori, H. Sakamoto, S. Morinaga, O. Kainuma, K. Imai, N. Sata, S. Hishinuma, H. Ojima, R. Yamaguchi, S. Hirano, T. Sudo, Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01). Eur. J. Cancer 93, 79–88 (2018)CrossRef Y. Hagiwara, Y. Ohashi, K. Uesaka, N. Boku, A. Fukutomi, Y. Okamura, M. Konishi, I. Matsumoto, Y. Kaneoka, Y. Shimizu, S. Nakamori, H. Sakamoto, S. Morinaga, O. Kainuma, K. Imai, N. Sata, S. Hishinuma, H. Ojima, R. Yamaguchi, S. Hirano, T. Sudo, Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01). Eur. J. Cancer 93, 79–88 (2018)CrossRef